Resources for Rare Disease Drug Discovery

New approaches to facilitate swift and successful drug development are needed. In response to this need, there is an increasing shift towards true partnership and active collaboration across academia, industry, and contract research organizations (CROs). Groundbreaking research that identifies new disease are the foundation that biotech and pharma companies use in partnership with CROs to develop targeted therapies. At Charles River, our scientific teams use iPS and d patient derived cell models, as well as new and established animal models to test new therapeutic modalities specific to rare disease and identify new endpoints.